ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Research Report 2024
Published Date: April 2024
|
Report Code: QYRE-Auto-28F16700
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Influenza Vaccine Split Virion Inactivated Quadrivalent Market Research Report 2024
BUY CHAPTERS

Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Research Report 2024

Code: QYRE-Auto-28F16700
Report
April 2024
Pages:78
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
SINOVAC BIOTECH
Sanofi
CSL Seqirus
GSK
Adimmune
Sinopharm
Jiangsu GDK Biotechnology
Abbott
Ab&B BIO-TECH
Hualan Bacterin

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent refers to an inactivated split influenza vaccine whose vaccine components include A (H3N2) subtype, A (H1N1) pdm09 subtype, and type B Victoria and Yamagata lines.
The global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent include Hualan Bacterin, Sinovac Biotech, Sanofi, CSL Seqirus, GSK, Adimmune, Sinopharm, Jiangsu GDK Biotechnology, Abbott, Ab&B BIO-TECH, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza Vaccine (Split Virion), Inactivated, Quadrivalent.
The Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Report

Report Metric Details
Report Name Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market
Segment by Type
  • Child
  • Adult
  • Elder
Segment by Application
  • Hospital
  • Clinic
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Hualan Bacterin, Sinovac Biotech, Sanofi, CSL Seqirus, GSK, Adimmune, Sinopharm, Jiangsu GDK Biotechnology, Abbott, Ab&B BIO-TECH
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market report?

Ans: The main players in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market are Hualan Bacterin, Sinovac Biotech, Sanofi, CSL Seqirus, GSK, Adimmune, Sinopharm, Jiangsu GDK Biotechnology, Abbott, Ab&B BIO-TECH

What are the Application segmentation covered in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market report?

Ans: The Applications covered in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market report are Hospital, Clinic

What are the Type segmentation covered in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market report?

Ans: The Types covered in the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market report are Child, Adult, Elder

1 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Overview
1.1 Product Definition
1.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Type
1.2.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Value Comparison by Type (2024-2030)
1.2.2 Child
1.2.3 Adult
1.2.4 Elder
1.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Application
1.3.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size Estimates and Forecasts
1.4.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue 2019-2030
1.4.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales 2019-2030
1.4.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Competition by Manufacturers
2.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Manufacturers (2019-2024)
2.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Product Type & Application
2.7 Global Key Manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Date of Enter into This Industry
2.8 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Competitive Situation and Trends
2.8.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Players Market Share by Revenue
2.8.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Scenario by Region
3.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region: 2019-2030
3.2.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region: 2019-2024
3.2.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region: 2025-2030
3.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region: 2019-2030
3.3.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region: 2019-2024
3.3.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region: 2025-2030
3.4 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Facts & Figures by Country
3.4.1 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2030)
3.4.3 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Facts & Figures by Country
3.5.1 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2030)
3.5.3 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Facts & Figures by Region
3.6.1 Asia Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region (2019-2030)
3.6.3 Asia Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Facts & Figures by Country
3.7.1 Latin America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2030)
3.7.3 Latin America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Facts & Figures by Country
3.8.1 Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2030)
3.8.3 Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2019-2030)
4.1.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2019-2024)
4.1.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Type (2025-2030)
4.1.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Type (2019-2030)
4.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Type (2019-2030)
4.2.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Type (2019-2024)
4.2.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Type (2025-2030)
4.2.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Type (2019-2030)
4.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Price by Type (2019-2030)
5 Segment by Application
5.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2019-2030)
5.1.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2019-2024)
5.1.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Application (2025-2030)
5.1.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Application (2019-2030)
5.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Application (2019-2030)
5.2.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Application (2019-2024)
5.2.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Application (2025-2030)
5.2.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Application (2019-2030)
5.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Hualan Bacterin
6.1.1 Hualan Bacterin Company Information
6.1.2 Hualan Bacterin Description and Business Overview
6.1.3 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolio
6.1.5 Hualan Bacterin Recent Developments/Updates
6.2 Sinovac Biotech
6.2.1 Sinovac Biotech Company Information
6.2.2 Sinovac Biotech Description and Business Overview
6.2.3 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolio
6.2.5 Sinovac Biotech Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 CSL Seqirus
6.4.1 CSL Seqirus Company Information
6.4.2 CSL Seqirus Description and Business Overview
6.4.3 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue and Gross Margin (2019-2024)
6.4.4 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolio
6.4.5 CSL Seqirus Recent Developments/Updates
6.5 GSK
6.5.1 GSK Company Information
6.5.2 GSK Description and Business Overview
6.5.3 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue and Gross Margin (2019-2024)
6.5.4 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolio
6.5.5 GSK Recent Developments/Updates
6.6 Adimmune
6.6.1 Adimmune Company Information
6.6.2 Adimmune Description and Business Overview
6.6.3 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolio
6.6.5 Adimmune Recent Developments/Updates
6.7 Sinopharm
6.7.1 Sinopharm Company Information
6.7.2 Sinopharm Description and Business Overview
6.7.3 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolio
6.7.5 Sinopharm Recent Developments/Updates
6.8 Jiangsu GDK Biotechnology
6.8.1 Jiangsu GDK Biotechnology Company Information
6.8.2 Jiangsu GDK Biotechnology Description and Business Overview
6.8.3 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolio
6.8.5 Jiangsu GDK Biotechnology Recent Developments/Updates
6.9 Abbott
6.9.1 Abbott Company Information
6.9.2 Abbott Description and Business Overview
6.9.3 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolio
6.9.5 Abbott Recent Developments/Updates
6.10 Ab&B BIO-TECH
6.10.1 Ab&B BIO-TECH Company Information
6.10.2 Ab&B BIO-TECH Description and Business Overview
6.10.3 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product Portfolio
6.10.5 Ab&B BIO-TECH Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Industry Chain Analysis
7.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Production Mode & Process
7.4 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales and Marketing
7.4.1 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Channels
7.4.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Distributors
7.5 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Customers
8 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Dynamics
8.1 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Industry Trends
8.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Drivers
8.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Challenges
8.4 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
SINOVAC BIOTECH
Sanofi
CSL Seqirus
GSK
Adimmune
Sinopharm
Jiangsu GDK Biotechnology
Abbott
Ab&B BIO-TECH
Hualan Bacterin
List of Tables
 Table 1. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Product Type & Application
 Table 12. Global Key Manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Vaccine (Split Virion), Inactivated, Quadrivalent as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region (2019-2024) & (K Units)
 Table 18. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Region (2019-2024)
 Table 19. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region (2025-2030) & (K Units)
 Table 20. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Region (2025-2030)
 Table 21. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Region (2019-2024)
 Table 23. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Region (2025-2030)
 Table 25. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2024) & (K Units)
 Table 27. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2025-2030) & (K Units)
 Table 28. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units) by Type (2019-2024)
 Table 51. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units) by Type (2025-2030)
 Table 52. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Type (2019-2024)
 Table 53. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Type (2025-2030)
 Table 54. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Type (2019-2024)
 Table 57. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Type (2025-2030)
 Table 58. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units) by Application (2019-2024)
 Table 61. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units) by Application (2025-2030)
 Table 62. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Application (2019-2024)
 Table 63. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Application (2025-2030)
 Table 64. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Application (2019-2024)
 Table 67. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Application (2025-2030)
 Table 68. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Price (US$/Unit) by Application (2025-2030)
 Table 70. Hualan Bacterin Company Information
 Table 71. Hualan Bacterin Description and Business Overview
 Table 72. Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product
 Table 74. Hualan Bacterin Recent Developments/Updates
 Table 75. Sinovac Biotech Company Information
 Table 76. Sinovac Biotech Description and Business Overview
 Table 77. Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product
 Table 79. Sinovac Biotech Recent Developments/Updates
 Table 80. Sanofi Company Information
 Table 81. Sanofi Description and Business Overview
 Table 82. Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product
 Table 84. Sanofi Recent Developments/Updates
 Table 85. CSL Seqirus Company Information
 Table 86. CSL Seqirus Description and Business Overview
 Table 87. CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product
 Table 89. CSL Seqirus Recent Developments/Updates
 Table 90. GSK Company Information
 Table 91. GSK Description and Business Overview
 Table 92. GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product
 Table 94. GSK Recent Developments/Updates
 Table 95. Adimmune Company Information
 Table 96. Adimmune Description and Business Overview
 Table 97. Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product
 Table 99. Adimmune Recent Developments/Updates
 Table 100. Sinopharm Company Information
 Table 101. Sinopharm Description and Business Overview
 Table 102. Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product
 Table 104. Sinopharm Recent Developments/Updates
 Table 105. Jiangsu GDK Biotechnology Company Information
 Table 106. Jiangsu GDK Biotechnology Description and Business Overview
 Table 107. Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product
 Table 109. Jiangsu GDK Biotechnology Recent Developments/Updates
 Table 110. Abbott Company Information
 Table 111. Abbott Description and Business Overview
 Table 112. Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product
 Table 114. Abbott Recent Developments/Updates
 Table 115. Ab&B BIO-TECH Company Information
 Table 116. Ab&B BIO-TECH Description and Business Overview
 Table 117. Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product
 Table 119. Ab&B BIO-TECH Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Distributors List
 Table 123. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Customers List
 Table 124. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Trends
 Table 125. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Drivers
 Table 126. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Challenges
 Table 127. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
 Figure 2. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Share by Type: 2023 & 2030
 Figure 4. Child Product Picture
 Figure 5. Adult Product Picture
 Figure 6. Elder Product Picture
 Figure 7. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Value by Application (2024-2030) & (US$ Million)
 Figure 8. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Share by Application: 2023 & 2030
 Figure 9. Hospital
 Figure 10. Clinic
 Figure 11. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 12. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size (2019-2030) & (US$ Million)
 Figure 13. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales (2019-2030) & (K Units)
 Figure 14. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price (US$/Unit) & (2019-2030)
 Figure 15. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Report Years Considered
 Figure 16. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Share by Manufacturers in 2023
 Figure 17. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Share by Manufacturers in 2023
 Figure 18. Global 5 and 10 Largest Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Players: Market Share by Revenue in Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in 2023
 Figure 19. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 20. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 21. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Country (2019-2030)
 Figure 22. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Country (2019-2030)
 Figure 23. United States Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 24. Canada Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Country (2019-2030)
 Figure 26. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Country (2019-2030)
 Figure 27. Germany Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. France Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. U.K. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. Italy Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Russia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Asia Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Region (2019-2030)
 Figure 33. Asia Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Region (2019-2030)
 Figure 34. China Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Japan Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. South Korea Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. India Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Australia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. China Taiwan Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Southeast Asia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Latin America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Country (2019-2030)
 Figure 42. Mexico Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Brazil Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Argentina Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Colombia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Market Share by Country (2019-2030)
 Figure 47. Middle East and Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Country (2019-2030)
 Figure 48. Turkey Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Saudi Arabia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. UAE Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Global Sales Market Share of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Type (2019-2030)
 Figure 52. Global Revenue Market Share of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Type (2019-2030)
 Figure 53. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Price (US$/Unit) by Type (2019-2030)
 Figure 54. Global Sales Market Share of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Application (2019-2030)
 Figure 55. Global Revenue Market Share of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Application (2019-2030)
 Figure 56. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Price (US$/Unit) by Application (2019-2030)
 Figure 57. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Value Chain
 Figure 58. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Production Process
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Global Trivalent Split Influenza Vaccine Market Research Report 2025
Split Influenza Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Tetravalent Influenza Virus Lysate Vaccine Market Research Report 2024
Global Inactivated Poultry Vaccine Market Research Report 2025
Global Influenza Subunit Vaccine Market Research Report 2024
Inactivated Vaccine Market
Reassortant Avian Influenza Virus Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Inactivated Influenza Virus Vaccine Market Research Report 2025
Global Trivalent Inactivated Influenza Vaccine Market Research Report 2025
Influenza Virus Vaccine H1N1 Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Multivalent Influenza Vaccines Market Research Report 2025
Global Vaccine for Influenza Market Research Report 2025
Global Pandemic Influenza Vaccine Market Research Report 2025
Global Adjuvanted Influenza Vaccine Market Research Report 2024
Global Equine Influenza Vaccine Market Research Report 2024
Inactivated Influenza Vaccine Market
Global Inactivated Poultry Vaccines Market Research Report 2024
Poliovirus Vaccine Inactivated Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Influenza Virus Vector Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Quadrivalent Flu Vaccine Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions